SCHEMBL38666141

SCHEMBL38666141

CC1([C@H](NC(=O)c2ccc3cc(F)ccc3c2OCc2ccc(OC(F)(F)F)cc2)C(=O)O)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CXCR2 P25025 2/20 0.38
▸ FFAR4 Q5NUL3 1/20 0.36
▸ OPRM1 P35372 1/20 0.35
▸ PPARA Q07869 2/20 0.35
▸ GCGR P47871 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ PTGDR2 Q9Y5Y4 1/20 0.34
▸ GPR132 Q9UNW8 1/20 0.34
▸ MAOB P27338 2/20 0.34
▸ MAOA P21397 2/20 0.34
▸ MRGPRX4 Q96LA9 1/20 0.34
▸ TRPV1 Q8NER1 1/20 0.34
▸ IDH1 O75874 1/20 0.34
▸ SLC2A1 P11166 1/20 0.34
▸ SLC2A3 P11169 1/20 0.34
▸ SLC2A4 P14672 1/20 0.34
▸ METAP2 P50579 1/20 0.33
▸ PPARD Q03181 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23461079 1.00 CXCR2 (0.38) CXCR2FFAR4OPRM1PPARAGCGR
SCHEMBL23461080 1.00 CXCR2 (0.38) CXCR2FFAR4OPRM1PPARAGCGR
SCHEMBL23461461 0.97 CXCR2 (0.37) CXCR2FFAR4OPRM1PPARAGCGR
SCHEMBL38146994 0.97 CXCR2 (0.37) CXCR2FFAR4OPRM1PPARAGCGR
SCHEMBL23461460 0.97 CXCR2 (0.37) CXCR2FFAR4OPRM1PPARAGCGR
SCHEMBL38663896 0.93 OPRM1 (0.37) CXCR2FFAR4OPRM1PPARAGCGR
SCHEMBL23460872 0.93 OPRM1 (0.37) CXCR2FFAR4OPRM1PPARAGCGR
SCHEMBL23460869 0.93 OPRM1 (0.37) CXCR2FFAR4OPRM1PPARAGCGR
SCHEMBL23461018 0.90 CXCR2 (0.47) CXCR2PPARAPPARD
SCHEMBL38146980 0.90 CXCR2 (0.47) CXCR2PPARAPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630498-B2 Arylamides and methods of use thereof GENZYME CORPORATION (US) 2026-05-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12630498-B2 Arylamides and methods of use thereof CFTR, CLIC1, CLCN2 CXCR2 63/4885FFAR4 1281/4885OPRM1 404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback